Synergy testing of FDA-approved drugs identifies potent drug combinations against Trypanosoma cruzi.
An estimated 8 million persons, mainly in Latin America, are infected with Trypanosoma cruzi, the etiologic agent of Chagas disease. Existing antiparasitic drugs for Chagas disease have significant toxicities and suboptimal effectiveness, hence new therapeutic strategies need to be devised to addres...
Main Authors: | Joseph D Planer, Matthew A Hulverson, Jennifer A Arif, Ranae M Ranade, Robert Don, Frederick S Buckner |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-07-01
|
Series: | PLoS Neglected Tropical Diseases |
Online Access: | http://europepmc.org/articles/PMC4102417?pdf=render |
Similar Items
-
Screening of FDA-Approved Drug Library Identifies Adefovir Dipivoxil as Highly Potent Inhibitor of T Cell Proliferation
by: Linda Voss, et al.
Published: (2021-01-01) -
Announcement Effect of Drug Approvals by FDA
by: Ting, Hsiu Wen, et al.
Published: (2008) -
Dodecyl-TPP Targets Mitochondria and Potently Eradicates Cancer Stem Cells (CSCs): Synergy With FDA-Approved Drugs and Natural Compounds (Vitamin C and Berberine)
by: Ernestina Marianna De Francesco, et al.
Published: (2019-08-01) -
Repositioning FDA Drugs as Potential Cruzain Inhibitors from Trypanosoma cruzi: Virtual Screening, In Vitro and In Vivo Studies
by: Isidro Palos, et al.
Published: (2017-06-01) -
FDA-Approved Drugs with Potent In Vitro Antiviral Activity against Severe Acute Respiratory Syndrome Coronavirus 2
by: Ahmed Mostafa, et al.
Published: (2020-12-01)